Skip to content

Study · Animal study (in vivo) · rat · 2024

14 results

Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint.

Vukusic D, Zenko Sever A, Sever M, Drmic D, Milavic M, Sikiric S, Rasic D, Krezic I, Gojkovic S, Prtoric A, Bubalo P, Coric L and 6 more

Show all authors

Dobric I, Boban Blagaic A, Rasic Z, Skrtic A, Seiwerth S, Sikiric P

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society1 Feb 2024Cited by 4 (Europe PMC)

PMID38583442 (opens in a new tab)DOI10.26402/jpp.2024.1.09 (opens in a new tab)PepBankPUB-38583442
Publisher pagePubMedAsk about this study
Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with a duodenocolic fistula, BPC‑157 rapidly induced vessel recruitment toward the defect at both duodenum and colon, with many collaterals and branching.

    In plain wordsIn rats with a bowel fistula, BPC‑157 quickly drew blood vessels toward the defect.

    Peptide
    BPC-157
    Outcome
    IncreaseVessel recruitment at fistula creation
    Study

    ratn: not reported in source

    Duodenocolic fistula
    Outcome group
    Wound healing · Gastrointestinal
    Studied dose
    10 μg/kg and 10 ng/kg · local at the fistula, intragastric, oral or intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    Upon duodenocolic fistula creation (two 'perforated' lesions put together) (assessed at 3, 6, 9, 12, and 15 min), BPC 157, given locally at the fistula, or intragastrically (10 μg/kg, 10 ng/kg), rapidly induces vessel 'recruitment', 'running' toward the defect, simultaneously at duodenum and colon,…
    2 context sentences
    Title · context
    Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint.
    Summary · context
    As therapy, rats with duodenocolic fistulas, received BPC 157 10 μg/kg, 10 ng/kg, per-orally, in drinking water till sacrifice, or alternatively, intraperitoneally, first application at 30 min after surgery, last at 24 h before sacrifice, at day 1, 3, 7, 14, 21, and 28.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In rats with a duodenocolic fistula, BPC‑157 strongly elevated nitric oxide synthase 2 gene expression.

    In plain wordsIn rats with a bowel fistula, BPC‑157 raised activity of the nitric oxide synthase 2 gene.

    Peptide
    BPC-157
    Outcome
    IncreaseNitric oxide synthase 2 mRNA expression
    Study

    ratn: not reported in source

    Duodenocolic fistula
    Outcome group
    Receptor activity and mechanism · Gastrointestinal
    Studied dose
    10 μg/kg and 10 ng/kg · local at the fistula, intragastric, oral or intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    The mRNA expression studies done at that time provided strongly elevated (nitric oxide synthase 2) and decreased (cyclooxygenase-2, vascular endothelial growth factor A, nitric oxide synthase (NOS)-1, NOS-3, nuclear factor-kappa-B-activating protein) gene expression.
    2 context sentences
    Title · context
    Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint.
    Summary · context
    As therapy, rats with duodenocolic fistulas, received BPC 157 10 μg/kg, 10 ng/kg, per-orally, in drinking water till sacrifice, or alternatively, intraperitoneally, first application at 30 min after surgery, last at 24 h before sacrifice, at day 1, 3, 7, 14, 21, and 28.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In rats with a duodenocolic fistula, BPC‑157 decreased cyclooxygenase-2 gene expression.

    In plain wordsIn rats with a bowel fistula, BPC‑157 lowered activity of the cyclooxygenase-2 gene.

    Peptide
    BPC-157
    Outcome
    DecreaseCyclooxygenase-2 mRNA expression
    Study

    ratn: not reported in source

    Duodenocolic fistula
    Outcome group
    Inflammation markers · Gastrointestinal
    Studied dose
    10 μg/kg and 10 ng/kg · local at the fistula, intragastric, oral or intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    The mRNA expression studies done at that time provided strongly elevated (nitric oxide synthase 2) and decreased (cyclooxygenase-2, vascular endothelial growth factor A, nitric oxide synthase (NOS)-1, NOS-3, nuclear factor-kappa-B-activating protein) gene expression.
    2 context sentences
    Title · context
    Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint.
    Summary · context
    As therapy, rats with duodenocolic fistulas, received BPC 157 10 μg/kg, 10 ng/kg, per-orally, in drinking water till sacrifice, or alternatively, intraperitoneally, first application at 30 min after surgery, last at 24 h before sacrifice, at day 1, 3, 7, 14, 21, and 28.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In rats with a duodenocolic fistula, BPC‑157 decreased vascular endothelial growth factor A gene expression.

    In plain wordsIn rats with a bowel fistula, BPC‑157 lowered activity of the VEGF-A gene.

    Peptide
    BPC-157
    Outcome
    DecreaseVascular endothelial growth factor A mRNA expression
    Study

    ratn: not reported in source

    Duodenocolic fistula
    Outcome group
    Receptor activity and mechanism · Gastrointestinal
    Studied dose
    10 μg/kg and 10 ng/kg · local at the fistula, intragastric, oral or intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    The mRNA expression studies done at that time provided strongly elevated (nitric oxide synthase 2) and decreased (cyclooxygenase-2, vascular endothelial growth factor A, nitric oxide synthase (NOS)-1, NOS-3, nuclear factor-kappa-B-activating protein) gene expression.
    2 context sentences
    Title · context
    Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint.
    Summary · context
    As therapy, rats with duodenocolic fistulas, received BPC 157 10 μg/kg, 10 ng/kg, per-orally, in drinking water till sacrifice, or alternatively, intraperitoneally, first application at 30 min after surgery, last at 24 h before sacrifice, at day 1, 3, 7, 14, 21, and 28.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In rats with a duodenocolic fistula, BPC‑157 decreased nitric oxide synthase-1 gene expression.

    In plain wordsIn rats with a bowel fistula, BPC‑157 lowered activity of the nitric oxide synthase-1 gene.

    Peptide
    BPC-157
    Outcome
    DecreaseNitric oxide synthase-1 mRNA expression
    Study

    ratn: not reported in source

    Duodenocolic fistula
    Outcome group
    Receptor activity and mechanism · Gastrointestinal
    Studied dose
    10 μg/kg and 10 ng/kg · local at the fistula, intragastric, oral or intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    The mRNA expression studies done at that time provided strongly elevated (nitric oxide synthase 2) and decreased (cyclooxygenase-2, vascular endothelial growth factor A, nitric oxide synthase (NOS)-1, NOS-3, nuclear factor-kappa-B-activating protein) gene expression.
    2 context sentences
    Title · context
    Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint.
    Summary · context
    As therapy, rats with duodenocolic fistulas, received BPC 157 10 μg/kg, 10 ng/kg, per-orally, in drinking water till sacrifice, or alternatively, intraperitoneally, first application at 30 min after surgery, last at 24 h before sacrifice, at day 1, 3, 7, 14, 21, and 28.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In rats with a duodenocolic fistula, BPC‑157 decreased nitric oxide synthase-3 gene expression.

    In plain wordsIn rats with a bowel fistula, BPC‑157 lowered activity of the nitric oxide synthase-3 gene.

    Peptide
    BPC-157
    Outcome
    DecreaseNitric oxide synthase-3 mRNA expression
    Study

    ratn: not reported in source

    Duodenocolic fistula
    Outcome group
    Receptor activity and mechanism · Gastrointestinal
    Studied dose
    10 μg/kg and 10 ng/kg · local at the fistula, intragastric, oral or intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    The mRNA expression studies done at that time provided strongly elevated (nitric oxide synthase 2) and decreased (cyclooxygenase-2, vascular endothelial growth factor A, nitric oxide synthase (NOS)-1, NOS-3, nuclear factor-kappa-B-activating protein) gene expression.
    2 context sentences
    Title · context
    Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint.
    Summary · context
    As therapy, rats with duodenocolic fistulas, received BPC 157 10 μg/kg, 10 ng/kg, per-orally, in drinking water till sacrifice, or alternatively, intraperitoneally, first application at 30 min after surgery, last at 24 h before sacrifice, at day 1, 3, 7, 14, 21, and 28.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In rats with a duodenocolic fistula, BPC‑157 decreased nuclear factor-kappa-B-activating protein gene expression.

    In plain wordsIn rats with a bowel fistula, BPC‑157 lowered activity of the NF-kappa-B-activating protein gene.

    Peptide
    BPC-157
    Outcome
    DecreaseNF-kappa-B-activating protein mRNA expression
    Study

    ratn: not reported in source

    Duodenocolic fistula
    Outcome group
    Inflammation markers · Gastrointestinal
    Studied dose
    10 μg/kg and 10 ng/kg · local at the fistula, intragastric, oral or intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    The mRNA expression studies done at that time provided strongly elevated (nitric oxide synthase 2) and decreased (cyclooxygenase-2, vascular endothelial growth factor A, nitric oxide synthase (NOS)-1, NOS-3, nuclear factor-kappa-B-activating protein) gene expression.
    2 context sentences
    Title · context
    Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint.
    Summary · context
    As therapy, rats with duodenocolic fistulas, received BPC 157 10 μg/kg, 10 ng/kg, per-orally, in drinking water till sacrifice, or alternatively, intraperitoneally, first application at 30 min after surgery, last at 24 h before sacrifice, at day 1, 3, 7, 14, 21, and 28.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In rats with a duodenocolic fistula, all BPC‑157-treated rats closed both the duodenal and the colonic defect, while controls kept both defects.

    In plain wordsIn rats with a bowel fistula, all rats given BPC‑157 closed both holes; control rats kept both.

    Peptide
    BPC-157
    Outcome
    IncreaseClosure of duodenal and colonic defects
    Study

    ratn: not reported in source

    Duodenocolic fistula
    Comparator
    Controls
    Outcome group
    Wound healing · Gastrointestinal
    Studied dose
    10 μg/kg and 10 ng/kg · local at the fistula, intragastric, oral or intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    all BPC 157-treated rats have closed both defects, duodenal and colonic
    3 context sentences
    Summary · context
    Controls exhibited both defects persisting, continuous fistula leakage, diarrhea, continuous weight loss, advanced adhesion formation and intestinal obstruction.
    Title · context
    Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint.
    Summary · context
    As therapy, rats with duodenocolic fistulas, received BPC 157 10 μg/kg, 10 ng/kg, per-orally, in drinking water till sacrifice, or alternatively, intraperitoneally, first application at 30 min after surgery, last at 24 h before sacrifice, at day 1, 3, 7, 14, 21, and 28.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In rats with a duodenocolic fistula, BPC‑157-treated rats had no fistula leakage, while controls had continuous leakage.

    In plain wordsIn rats with a bowel fistula, rats given BPC‑157 had no leakage; control rats leaked continuously.

    Peptide
    BPC-157
    Outcome
    DecreaseFistula leakage
    Study

    ratn: not reported in source

    Duodenocolic fistula
    Comparator
    Controls
    Outcome group
    Wound healing · Gastrointestinal
    Studied dose
    10 μg/kg and 10 ng/kg · local at the fistula, intragastric, oral or intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    no fistula leakage (finally, maximal instilled volume corresponds to healthy rats)
    3 context sentences
    Summary · context
    Controls exhibited both defects persisting, continuous fistula leakage, diarrhea, continuous weight loss, advanced adhesion formation and intestinal obstruction.
    Title · context
    Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint.
    Summary · context
    As therapy, rats with duodenocolic fistulas, received BPC 157 10 μg/kg, 10 ng/kg, per-orally, in drinking water till sacrifice, or alternatively, intraperitoneally, first application at 30 min after surgery, last at 24 h before sacrifice, at day 1, 3, 7, 14, 21, and 28.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In rats with a duodenocolic fistula, BPC‑157-treated rats had no cachexia, while controls kept losing weight.

    In plain wordsIn rats with a bowel fistula, rats given BPC‑157 did not waste away; control rats kept losing weight.

    Peptide
    BPC-157
    Outcome
    DecreaseCachexia
    Study

    ratn: not reported in source

    Duodenocolic fistula
    Comparator
    Controls
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 μg/kg and 10 ng/kg · local at the fistula, intragastric, oral or intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    no cachexia, the same weight as before surgery, no diarrhea, markedly less adhesion formation and intestinal passage obstruction.
    3 context sentences
    Summary · context
    Controls exhibited both defects persisting, continuous fistula leakage, diarrhea, continuous weight loss, advanced adhesion formation and intestinal obstruction.
    Title · context
    Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint.
    Summary · context
    As therapy, rats with duodenocolic fistulas, received BPC 157 10 μg/kg, 10 ng/kg, per-orally, in drinking water till sacrifice, or alternatively, intraperitoneally, first application at 30 min after surgery, last at 24 h before sacrifice, at day 1, 3, 7, 14, 21, and 28.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In rats with a duodenocolic fistula, BPC‑157-treated rats kept the same weight as before surgery, while controls had continuous weight loss.

    In plain wordsIn rats with a bowel fistula, rats given BPC‑157 kept their weight; control rats kept losing weight.

    Peptide
    BPC-157
    Outcome
    IncreaseBody weight relative to pre-surgery
    Study

    ratn: not reported in source

    Duodenocolic fistula
    Comparator
    Controls
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 μg/kg and 10 ng/kg · local at the fistula, intragastric, oral or intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    the same weight as before surgery, no diarrhea, markedly less adhesion formation and intestinal passage obstruction.
    3 context sentences
    Summary · context
    Controls exhibited both defects persisting, continuous fistula leakage, diarrhea, continuous weight loss, advanced adhesion formation and intestinal obstruction.
    Title · context
    Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint.
    Summary · context
    As therapy, rats with duodenocolic fistulas, received BPC 157 10 μg/kg, 10 ng/kg, per-orally, in drinking water till sacrifice, or alternatively, intraperitoneally, first application at 30 min after surgery, last at 24 h before sacrifice, at day 1, 3, 7, 14, 21, and 28.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In rats with a duodenocolic fistula, BPC‑157-treated rats had no diarrhea, while controls had diarrhea.

    In plain wordsIn rats with a bowel fistula, rats given BPC‑157 had no diarrhea; control rats did.

    Peptide
    BPC-157
    Outcome
    DecreaseDiarrhea
    Study

    ratn: not reported in source

    Duodenocolic fistula
    Comparator
    Controls
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 μg/kg and 10 ng/kg · local at the fistula, intragastric, oral or intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    no diarrhea, markedly less adhesion formation and intestinal passage obstruction.
    3 context sentences
    Summary · context
    Controls exhibited both defects persisting, continuous fistula leakage, diarrhea, continuous weight loss, advanced adhesion formation and intestinal obstruction.
    Title · context
    Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint.
    Summary · context
    As therapy, rats with duodenocolic fistulas, received BPC 157 10 μg/kg, 10 ng/kg, per-orally, in drinking water till sacrifice, or alternatively, intraperitoneally, first application at 30 min after surgery, last at 24 h before sacrifice, at day 1, 3, 7, 14, 21, and 28.
  13. 13AnimalAnimal study (in vivo)Efficacy outcome

    In rats with a duodenocolic fistula, BPC‑157-treated rats had markedly less adhesion formation than controls with advanced adhesion formation.

    In plain wordsIn rats with a bowel fistula, rats given BPC‑157 had much less scar-like sticking of tissue than control rats.

    Peptide
    BPC-157
    Outcome
    DecreaseAdhesion formation
    Study

    ratn: not reported in source

    Duodenocolic fistula
    Comparator
    Controls
    Outcome group
    Wound healing · Gastrointestinal
    Studied dose
    10 μg/kg and 10 ng/kg · local at the fistula, intragastric, oral or intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    markedly less adhesion formation and intestinal passage obstruction.
    3 context sentences
    Summary · context
    Controls exhibited both defects persisting, continuous fistula leakage, diarrhea, continuous weight loss, advanced adhesion formation and intestinal obstruction.
    Title · context
    Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint.
    Summary · context
    As therapy, rats with duodenocolic fistulas, received BPC 157 10 μg/kg, 10 ng/kg, per-orally, in drinking water till sacrifice, or alternatively, intraperitoneally, first application at 30 min after surgery, last at 24 h before sacrifice, at day 1, 3, 7, 14, 21, and 28.
  14. 14AnimalAnimal study (in vivo)Efficacy outcome

    In rats with a duodenocolic fistula, BPC‑157-treated rats had markedly less intestinal passage obstruction than controls, which had intestinal obstruction.

    In plain wordsIn rats with a bowel fistula, rats given BPC‑157 had much less bowel blockage than control rats.

    Peptide
    BPC-157
    Outcome
    DecreaseIntestinal passage obstruction
    Study

    ratn: not reported in source

    Duodenocolic fistula
    Comparator
    Controls
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 μg/kg and 10 ng/kg · local at the fistula, intragastric, oral or intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    intestinal passage obstruction.
    3 context sentences
    Summary · context
    Controls exhibited both defects persisting, continuous fistula leakage, diarrhea, continuous weight loss, advanced adhesion formation and intestinal obstruction.
    Title · context
    Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint.
    Summary · context
    As therapy, rats with duodenocolic fistulas, received BPC 157 10 μg/kg, 10 ng/kg, per-orally, in drinking water till sacrifice, or alternatively, intraperitoneally, first application at 30 min after surgery, last at 24 h before sacrifice, at day 1, 3, 7, 14, 21, and 28.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.